Aspen Biosciences

Gene therapy reduces chronic pain and chemo-induced peripheral neuropathy in mice | https://bit.ly/3YhrtQH

Gene therapy reduces chronic pain and chemo-induced peripheral neuropathy in mice Researchers have identified another potential gene therapy for treating chronic pain, this time by indirectly targeting a key sodium ion channel. | Researchers have identified another potential gene therapy for treating chronic pain, this time by indirectly targeting a key sodium ion channel.

Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio | https://bit.ly/47mektI

Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio Biogen agrees to acquire Reata Pharmaceuticals for approximately $7.3 billion, in a deal intended to bolster its neurological drug portfolio.

Check out the innovation in "Pipeline"!

This Program Management platform is a game-changer, guiding teams from Target Identification to Lead Optimization.
Email [email protected] for more info!

Today is International Friendship Day... We all have many acquaintances, but friends?

Those are special relationships. Friends provide support when needed, lift your spirits when you are down, and share the high's and low's of your life.

Super killer T-cells discovered in patients who beat cancer | https://bit.ly/3QmLDH3

Super killer T-cells discovered in patients who beat cancer Scientists have discovered a previously unknown type of immune cell that develops in people who successfully fight off cancer. Unlike other killer T cells, these home in on multiple cancer-associated targets at once, preventing new tumors forming for up to a year later and could lead to more…

Did you know?

https://bit.ly/3CtV2VC

Flipping a Switch and Making Cancers Self-Destruct | https://nyti.ms/44N90xy

Flipping a Switch and Making Cancers Self-Destruct Researchers at Stanford devised a strange new molecule that could lead to drugs that arm genes and make cancers work against themselves.

Sanofi, BioNTech cull mRNA clinical cytokine cancer candidate based on early data | https://bit.ly/3QhCKOF

Sanofi, BioNTech cull mRNA clinical cytokine cancer candidate based on early data Sanofi and BioNTech’s vision of using mRNA to prime anti-cancer immune attacks has failed to hold up to clinical scrutiny. | Sanofi and BioNTech’s vision of using mRNA to prime anti-cancer immune attacks has failed to hold up to clinical scrutiny. After running an interim analysis of early-phase...

Discover how FAIR (Meta)data can make or break operations.

Learn the importance of FAIR data, efforts to de-risk collaboration and data exchange, and what it will take for FAIR principles to be more ubiquitously adopted.

https://bit.ly/3Piaefq

In Vivo Genome Editing of Stem Cells Induced by LNP-Based Delivery of mRNA | https://bit.ly/3OxTmAp

In Vivo Genome Editing of Stem Cells Induced by LNP-Based Delivery of mRNA Researchers demonstrated in vivo genome editing of hematopoietic stem cells through mRNA delivered by LNPs decorated with targeting moieties.

We are committed to accelerating life science R&D efforts by removing technical obstacles that slow down scientific processes from Target Identification to Lead Generation.

Need integration of multiple systems/platforms? Contact [email protected] to see how we can help.

Merck’s next-gen pneumococcal vaccine strides forward after two phase 3 wins | https://bit.ly/3QiPPHB

Merck’s next-gen pneumococcal vaccine strides forward after two phase 3 wins Merck & Co.’s next-generation pneumococcal vaccine has secured success in a pair of phase 3 trials, bringing the Big Pharma within touching distance of getting the first pneumococcal conjugate | Merck & Co.’s next-generation pneumococcal vaccine has secured success in a pair of phase 3 trials, b...

It was another great showing this year at the San Diego CLSAdvantage Solutions showcase and networking event!

It was great being a sponsor and participating with the community at this event. A big Kudos to the organizers of the event California Life Sciences - CLS (CLS) and thank you to our fellow sponsors Avantor Nikon The Corporation Agilent beeip.com Technologies Global & , Cory, Hargreaves & Savitch LLP

Special thanks to and for heading up the table.👍 (Image by CLS)

New Therapeutic Approach Rewires Death Pathways to Jumpstart Apoptosis | https://bit.ly/3OyoOii

New Therapeutic Approach Rewires Death Pathways to Jumpstart Apoptosis Scientists discovered a class of molecules that use endogenous proteins to modulate genetic pathways involved in cell death.

Stoke Therapeutics unveils more data on studies of Dravet drug, hinting at improvements to cognition and behavior | https://bit.ly/453Tyx3

Stoke Therapeutics unveils more data on studies of Dravet drug, hinting at improvements to cognition and behavior Stoke Therapeutics presented more data on its investigational Dravet syndrome treatment on Tuesday morning, saying it helped reduce seizures and improve certain cognitive and behavioral functions, but the 45 mg data were well below analyst expectations and investors sent the stock $STOK down nearly....

Boehringer Ingelheim, Eli Lilly's Jardiance nabs approval in Europe for chronic kidney disease | https://bit.ly/3Y6BMH6

Boehringer Ingelheim, Eli Lilly's Jardiance nabs approval in Europe for chronic kidney disease Boehringer Ingelheim and Eli Lilly said Jardiance received approval in Europe as a treatment for chronic kidney disease in adults, with the FDA’s decision on the drug for that indication expected to come this year. Jardiance, or empagliflozin, has already been approved by the European Commission f...

Upgrade your program management tools with an integrable solution!

Pipeline: Innovative Drug Discovery Program Management software.

Want a lunch-n-learn for your scientific team (San Diego)?
Email Traci Murrie: [email protected]

Jim Momtazee's Patient Square leads $150M+ addition to Kriya Therapeutics' 'mainstream' gene therapy ambitions | https://bit.ly/3Ohlg2C

Jim Momtazee's Patient Square leads $150M+ addition to Kriya Therapeutics' 'mainstream' gene therapy ambitions Shankar Ramaswamy’s Kriya Therapeutics has upped its Series C with an additional $150 million-plus to take the biotech into late 2026. The AAV-focused gene therapy maker hopes to bring its first candidates to the clinic in the next 18 to 24 months, Ramaswamy, the co-founder and CEO, told Endpoints...

Two Types of T Cells Implicated in Fat and Muscle Wasting during Infection | Salk Institute Cell Reports https://bit.ly/3OxZFEp

Two Types of T Cells Implicated in Fat and Muscle Wasting during Infection Results showed fat loss did not benefit fight against T. brucei infection, but muscle loss did, indicating, surprisingly, that some wasting may help manage illness.

Gilead axes PhIII trial for CD47 drug in latest setback for $4.9B buyout | https://bit.ly/3Dv7nsC

Gilead axes PhIII trial for CD47 drug in latest setback for $4.9B buyout Gilead will scrap one of three Phase III trials for magrolimab, the anti-CD47 drug at the heart of its $4.9 billion acquisition of Forty Seven three years ago, while carrying on with the other two. In a late Friday statement, Gilead attributed the decision to “futility based on a planned

New discovery could prove pivotal in stopping cancer spreading | https://bit.ly/3OazsKJ

New discovery could prove pivotal in stopping cancer spreading In a discovery that took researchers by surprise, a protein known to play a crucial role in cancer growth has for the first time been observed traveling into cell nuclei to flick switches that make cancers more mobile, aggressive and invasive.

Don't forget to join us tonight at the CLSA San Diego Open House & Solutions Showcase!

Stop by our table - Talk to us about how about your technical obstacles.

https://bit.ly/3NGuYen

Aspen Biosciences welcomes Eric Robbibaro to its leadership team.

https://bit.ly/3rFl0Tb

Aspen Biosciences Announces Appointment of Eric Robbibaro As New Director of Sales Aspen Biosciences today announces the appointment of Eric Robbibaro as its new Director of Business in San Diego. Eric Robbibaro brings an impressive

New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy | https://bit.ly/3Y5oCKm

New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy Another mRNA vaccine for malaria is on the way. This time, its creators are taking a page from the cancer immunotherapy playbook to make it more effective. | Another mRNA vaccine for malaria is on the way. Its creators took a page from the cancer immunotherapy playbook to hopefully make it more effe...

Aspen Biosciences announces the appointment of Eric Robbibaro as its new Director of Business in San Diego.

Unexpected Role for Chaperone Protein in Cancer Spread | https://bit.ly/44DEdU4

Unexpected Role for Chaperone Protein in Cancer Spread When cancer cells are under stress, the ER chaperone GRP78 travels to the nucleus and reprograms the cell to migrate and become more invasive.

First Spatial Map of the Intestine at the Single-Cell Level | https://bit.ly/3pUR450

First Spatial Map of the Intestine at the Single-Cell Level New mapping effort, using spatial technology, reveals the organization of the human intestine at single-cell resolution for the first time.

New ALS Therapeutic Strategy Targets mRNA and Protein Distribution | https://bit.ly/3DkG2Jz

New ALS Therapeutic Strategy Targets mRNA and Protein Distribution Maintenance of mRNA and protein localization in motor neurons is a potential therapeutic avenue for Amyotrophic lateral sclerosis (ALS)

Streamline and lower risk in your drug discovery process.

This white paper provides resources available for drug discovery scientists and highlights Pipeline features to accelerate drug discovery.

https://bit.ly/3JmFwy6

It's not too late. Join us at the CLSA Networking event. In the spirit of ...We're showcasing "Pipeline", the Program Mgmt app for
- Configurable
- Modular
- Integrable

Email: [email protected]
https://bit.ly/3NGuYen